749932-17-0 Usage
General Description
4-Bromo-1-difluoromethyl-2-fluorobenzene is a chemical compound that belongs to the class of difluoromethylbenzene derivatives. It is a halogenated aromatic compound with the molecular formula C7H4BrF3. This chemical is commonly used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other fine chemicals. It exhibits a high level of reactivity and is often used as a building block in the production of more complex organic compounds. Additionally, 4-Bromo-1-difluoromethyl-2-fluorobenzene is used as a reagent in organic synthesis and as a reference standard in analytical chemistry. It is important to handle this chemical with caution due to its potential health hazards and environmental impact.
Check Digit Verification of cas no
The CAS Registry Mumber 749932-17-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,4,9,9,3 and 2 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 749932-17:
(8*7)+(7*4)+(6*9)+(5*9)+(4*3)+(3*2)+(2*1)+(1*7)=210
210 % 10 = 0
So 749932-17-0 is a valid CAS Registry Number.
InChI:InChI=1/C7H4BrF3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,7H
749932-17-0Relevant articles and documents
HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS
-
Page/Page column 45-46, (2018/07/05)
The present invention relates to a compound represented by formula (I) : and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
-
Page 320, (2008/06/13)
The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).